27.9 C
New York
Wednesday, June 10, 2026

Tag: cancers

newssourceFORcompanyinformationcontent1marketreleases

Biotech Stocks Rally as Oncology Market Targets $866B by 2034

Equity Insider News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Aug. 14, 2025 /PRNewswire/ -- Equity Insider News Commentary – Despite alarming federal budget cuts...

Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

– Live video webcast on Wednesday, August 20th at 2:00 PM ET

Chisholm Chisholm & Kilpatrick LTD and National Veterans Legal Services Program Challenge VA’s Denial of Benefits to Caregivers after Veterans’ Deaths

Class Actions Seeks to Represent Untold Number of Caregivers Who Appealed Denials from the VA's Program of Comprehensive Assistance for Family Caregivers WASHINGTON, Aug. 12,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

Tumor-Infiltrating Lymphocyte Therapy Market Gains Momentum with Expanding Oncology Applications | DelveInsight

Over the last ten years, cell-based immunotherapy has emerged as a promising approach for treating solid tumors. Several companies, including Iovance Biotherapeutics, Obsidian Therapeutics,...

FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease

— Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage — — BRINSUPRI 10...

Anixa Biosciences Announces Issuance of Additional U.S. Patent for CAR-T Technology

Newly issued patent extends protection of proprietary solid tumor CAR-T platform to 2045 SAN JOSE, Calif., Aug. 12, 2025 /PRNewswire/ -- Anixa Biosciences, Inc. ("Anixa"...

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

SAN DIEGO, Aug. 11, 2025 /PRNewswire/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company...

Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders

SAN DIEGO, Aug. 11, 2025 /CNW/ -- Oncolytics Biotech® Inc. (Nasdaq: ONCY) (TSX: ONC) ("Oncolytics" or the "Corporation" or the "Company"), a clinical-stage immunotherapy company...

Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900

REPEAT — Tevogen Bio Specialty Care Reports Top-Line Revenue Forecast of Nearly $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $18 Billion...

WARREN, N.J., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio (“Tevogen” or “Tevogen Bio Holdings Inc.”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech developing off-the-shelf, genetically unmodified T cell therapeutics to treat infectious disease and cancers, today announced its top-line revenue forecast for its specialty care pipeline, projecting nearly $1 billion in revenue in its launch year and a cumulative 5-year estimate of between $18 billion and $22 billion. This forecast reflects the company’s unique, faster, and cost-efficient drug development model which has the potential to serve as a blueprint to ensure sustainable medical innovation for years to come.

- A word from our sponsors -

spot_img
HomeTagsCancers

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers